HYPERTENSION, PULMONARY
Clinical trials for HYPERTENSION, PULMONARY explained in plain language.
Never miss a new study
Get alerted when new HYPERTENSION, PULMONARY trials appear
Sign up with your email to follow new studies for HYPERTENSION, PULMONARY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for PAH patients: Long-Term drug safety trial underway
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of the drug ralinepag in people with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. About 1,000 adults who have already been in earlier ralinepag studies will take the drug and be monitored f…
Matched conditions: HYPERTENSION, PULMONARY
Phase: PHASE3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New hope for kids with rare lung disease: drug trial shows promise
Disease control OngoingThis study tested the safety of a drug called riociguat in 24 children aged 6 to 17 with pulmonary arterial hypertension (PAH), a rare condition where high blood pressure affects the lungs. The drug was given in doses adjusted for each child's age, sex, and weight. The goal was t…
Matched conditions: HYPERTENSION, PULMONARY
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New hope for kids with rare lung disease: drug may slow worsening
Disease control OngoingThis study tests whether adding selexipag to standard treatment can delay disease worsening in children aged 2 to 18 with pulmonary arterial hypertension (PAH), a serious lung condition. About 138 children will receive either selexipag or a placebo alongside their usual care. The…
Matched conditions: HYPERTENSION, PULMONARY
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated Apr 24, 2026 16:18 UTC